Does Reticulocyte Hemoglobin Content (Ret-He) change in Anemia of Chronic Disease (ACD) and Iron Deficiency Anemia (IDA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Reticulocyte Hemoglobin Content Changes in ACD and IDA

Reticulocyte hemoglobin content (Ret-He) is significantly decreased in iron deficiency anemia (IDA) but can be normal or only slightly reduced in anemia of chronic disease (ACD), making it a valuable parameter for differentiating between these two conditions.

Ret-He Values in Different Types of Anemia

Iron Deficiency Anemia (IDA)

  • Ret-He is markedly decreased in IDA, typically below 30 pg 1, 2
  • At a cut-off value of 27 pg/mL, Ret-He can diagnose IDA with 93.4% sensitivity and 95.83% specificity 2
  • Ret-He decreases earlier than erythrocyte parameters due to reticulocytes' shorter lifespan (1-2 days vs 120 days for RBCs), making it an early indicator of iron-restricted erythropoiesis 2

Anemia of Chronic Disease (ACD)

  • Ret-He values are typically normal or only slightly reduced in pure ACD 1, 3
  • In ACD, inflammation-induced hepcidin upregulation creates functional iron deficiency despite adequate iron stores 4
  • The diagnostic criteria for ACD include serum ferritin >100 μg/L and transferrin saturation <20% in the presence of inflammation 4

Mixed ACD+IDA

  • Ret-He is decreased in mixed ACD+IDA, similar to pure IDA 1
  • When serum ferritin is between 30-100 μg/L with low transferrin saturation, a combination of IDA and ACD is likely 4

Clinical Utility of Ret-He

Diagnostic Performance

  • Ret-He shows excellent diagnostic performance with an area under curve (AUC) of 0.858 for detecting iron-deficient erythropoiesis 1
  • It outperforms the percentage of hypochromic erythrocytes (Hypo-He) which has an AUC of 0.727 1
  • Ret-He correlates positively with serum iron, ferritin, and TIBC in diagnosing IDA 2

Advantages in Clinical Practice

  • Provides real-time assessment of iron availability for erythropoiesis
  • Reflects short-term changes in iron status (compared to Hypo-He which reflects long-term changes) 1
  • Can be used as an alternative to bone marrow examination, which is invasive and cumbersome 2

Practical Application in Differential Diagnosis

Recommended Cut-off Values

  • Ret-He <30 pg: Highly suggestive of IDA (sensitivity 76.8%, specificity 99.8%) 1
  • Ret-He <27 pg: Optimal for diagnosing IDA (sensitivity 93.4%, specificity 95.83%) 2
  • Normal reference range for Ret-He: 28.2-35.7 pg 3

Combined Parameters for Better Accuracy

  • Using Ret-He in combination with soluble transferrin receptor/log ferritin ratio (sTfR-F index) improves diagnostic accuracy 3
  • The percentage of hypochromic erythrocytes (>1.8%) can help identify absolute iron deficiency in patients with ACD (sensitivity 72.7%, specificity 70.4%) 5

Limitations and Considerations

  • Ret-He correlations with biochemical iron markers are weaker in patients with ACD and acute phase response 3
  • No significant difference in Ret-He values between pure IDA and mixed ACD+IDA groups, making it difficult to distinguish between these two conditions 5
  • Inflammation can affect the interpretation of traditional iron parameters, requiring careful clinical correlation

By incorporating Ret-He measurement into the diagnostic workup of anemia, clinicians can more accurately differentiate between IDA and ACD, leading to more appropriate treatment decisions and improved patient outcomes.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.